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Currently, data showing a connection between allergen dosage and allergic sensitisation are scarce 31 since, generally, the pathophysiological mechanisms of sensitisation are only insufficiently 32 understood. In contrast, data on dose-distribution relationships acquired by oral food challenge are 33 available, showing a connection of allergenic protein consumed and the elicitation of allergic 34 reactions. Soybean as the currently only recognised allergenic GM food by law for which EFSA has 35 received applications for placement on the market was taken as an example for defining an 36 assessment strategy. This approach for endogenous allergenicity assessment in soybean could, in the 37 next step, be expanded to other allergenic foods in the future, whenever required. Identification of 38 potential soybean allergens, the methodology to be used as well as risk assessment considerations 39
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Introduction: 62
Allergen dosage is a critical issue in the course of the allergic disease, and possible overexpression of 63 allergenic proteins in plants used for food might pose a risk to allergic consumers' health. It is 64 therefore important to monitor food derived from modern biotechnology regarding allergenicity and, 65 if the food source is known to be allergenic, to evaluate the expression levels of endogenous 66
allergens. 67
The allergic disease is a two-step process made up by sensitisation to the allergenic food and 68 subsequent elicitation of the allergic reaction resulting in allergic symptoms when the allergen is 69 administered in sufficient amounts (Taylor et al., 2009 ). The dose necessary for allergic sensitisation 70 is only insufficiently studied and it is challenging to determine a threshold for sensitisation (Taylor et 71 al., 2009 ). Also, it has been shown that encountering potential allergenic foods under specific 72 circumstances at an early age might actually even lower the risk of food allergy (Du Toit et al., 2015) . 73
In contrast, the dose-distribution relationship for elicitation of an allergic reaction can be determined 74 by oral food challenge of allergic individuals with increasing doses of the allergenic food and the 75 minimum eliciting doses were determined for many allergenic food sources (Ballmer-Weber et al., 76 2015; Zhu et al., 2015) . For soybean, the minimum amount of protein causing objective symptoms in 77 allergic individuals was described to be 5.3 mg of soybean protein in one study (Ballmer-Weber et al., 78 2007), but others determined the lowest the dose resulting in observed adverse effect level (LOAEL) 79 to be as low as 0.2 mg of total protein used in food challenge (Blom et al., 2013) . However, 80 depending on the individual allergenic protein contained within consumed food and especially 81 depending on the single allergic individual and experimental procedures, this amount eliciting 82 objective symptoms can vary on a large scale, which is undermined by a sometimes poor 83 reproducibility of double blind placebo controlled food challenge (DBPCFC) (Glaumann et al., 2013) . 84
Allergic subjects are generally advised to altogether avoid food containing the respective allergenic 85 ingredients. However, unintentional ingestions of allergenic food happen on a regular basis and are 86 mostly the reason for adverse reactions in allergic individuals who are aware of their condition. 87
Several studies describing the prevalence of unintended exposure to food allergens have been 88 reviewed (Boyce et al., 2010) . On the other hand however, also intentional ingestions are not 89 uncommon. Especially young adults are willing to take risks, as 54% of 13-21 year old food allergic 90 allergic individuals admitted to eat small amounts of the food they are allergic to (Sampson, 2006) . experience that certain amounts of similar foods did not cause any allergic reactions previously 97 (Sampson et al., 2006) . It can therefore not be assumed that allergic subjects avoid the food they are 98 allergic to at all times, and, while this can happen unintentionally, they might also consume the 99 allergenic food consciously. 100
From a regulatory point of view, the assessment of endogenous allergenicity is a prerequisite before 101 any genetically modified (GM) plant known to be allergenic can be placed on the European market 102 (IR503/2013 EC, 2013). These guideline instructions are also in line with international standards 103 described in Codex Alimentarius (Codex, 2009 ). Here, the major strategy of risk assessors is to 104 determine whether GM food is as safe as the conventionally consumed non-GM comparator. To this 105 end, any GM plant regarded to be allergenic has to be evaluated for potential changes in allergen 106 composition by comparing the food source derived from modern biotechnology with appropriate 107 non-GM comparators. 108
Currently, provision of information to the consumers concerning food containing allergens is 109 mandatory under EU regulation No 1169/2011 (EC, 2011). However, it can be anticipated that a 110 reference level will be in place in the future, whereby the content of an allergic food source in the 111 overall product will be decisive if precautionary labelling is necessary. In products where the overall 112 amount of an allergic food source is too low and which will therefore not be labelled, the 113 endogenous allergen content gains crucial importance. A single allergen enhanced in the original 114 crop would then mean that even though the food product would still contain the same (low) amount 115 of protein from the allergen source, it might contain a multiple of the single allergenic protein. This 116 might pose a risk to particular allergic consumers who would be unaware of the content of the food 117 product. 118
Because of these facts and also because the impact of allergen dosage on sensitisation to potentially 119 allergenic proteins is only insufficiently understood, it is crucially important to know whether or not 120 the levels of endogenous allergens of a GM crop, in relation to appropriate comparators, have been 121 modified to a level that may cause concerns. To this end, a thorough investigation of endogenous 122 allergenicity of GM food and comparison with appropriate comparators is essential in order to inform 123 risk managers of (absence of) increased risks. with a better readout are available, which can be standardised more easily and do not depend on 209 limiting human material. 210
Because of the described limitations of quantifying endogenous allergens on the basis of human 211 serum IgE binding, the 2D-GE methodology was developed and used as an alternative. 2D-GE and 212 protein spot quantification by densitometry has been used previously to quantitatively assess five 213 potential soybean allergens in a GM soybean variety and non-GM comparators (Rouquie et al., 2010) . 214
In order to identify and quantify soybean proteins, including potential allergens, another group used 215 an 2D-GE and mass spectrometry based approach, also using spot intensity quantification (Natarajan 216 et al., 2009 ). However, the focus of this publication lies on identification of proteins rather than their 217 quantification. While these spot quantification methods might be an improvement compared to 218 those using human serum IgE, analyses not done simultaneously still cannot be compared. Therefore, 219 the methodology for the endogenous allergenicity assessment has recently moved towards absolute 220 quantification by mass spectrometry, as discussed previously (Fernandez et al., 2013) , and 221 quantitative ELISA based on IgG antibodies raised in animals. These appropriate methods for the 222 quantitative assessment of endogenous allergens will be described and discussed in more detail 223 below. 224
Identification of potential soybean allergens for assessment 225
The table provided in the OECD consensus document on soybean compositional considerations 226 (Table 20 in Table 1 lists the information collected for all potential soybean allergens after 232 applying this search (Table 1) . A more detailed version of the outcome can be found in the EFSA 233 public consultation document on the guidance on allergenicity assessment of GM plants (Table C1, Given the aforementioned mentioned challenges, the definitions of renowned, international 262 institutions like WHO can be used as a tool to define allergens. IUIS/WHO describes the IgE-reactivity 263 of at least 5 patient's sera with a specific molecule as a primary criterion for this purpose. In the next 264 step, an expert peer-review process is conducted before a protein is included among allergens in the 265 database. In table 1, the IUIS/WHO primary criteria were applied to the list of potential allergens as a 266 starting point. Considerations for including molecules into current endogenous allergenicity 267 assessments are described on the basis of the further strategy applied by IUIS/WHO, suggesting a 268 peer-review process, as well as on possible methodological limitations (Table 1) . A more detailed 269 description of this strategy can be found in the EFSA guidance document on allergenicity assessment 270 (EFSA public consultation document, 2016). It should be noted that, due to the constant progress in 271 science, these considerations might be outdated in the future, making adaptions necessary. 272
Methodology for the assessment of endogenous allergens 273
Well established and suitable methods to assess endogenous allergens are mass spectrometry and 274 quantitative ELISA. In ELISA, specific IgG antibodies well characterized for their specificity and affinity 275 should be used, which were raised in animals after immunisation with purified allergens. Examples 276 for endogenous allergenicity assessment of soybean from the current literature using these methods 277 are elaborated below. commercial soybean varieties. The authors concluded that some of the assessed proteins were highly 289 variable among the tested soybean crops. These variations were mainly found in two of the five 290 studied Gly m 6 subunits (i.e. G3 and G4) and in the Gly m 5 α-subunit. In another publication by the 291 same group, high endogenous allergen variability between varieties was concluded to be rather 292 connected to environmental conditions than to the variety itself. However, also the crop variety 293 played a role for some allergens (Stevenson et al., 2012) . ELISA method is a valuable and helpful tool to quantitatively assess endogenous allergens, and is able 312 to provide accurate readouts. However, it has to be assured that defined antibodies raised in animals 313 against single allergen molecules are used. Previously, also antibodies raised against whole soybean 314 protein extract were applied to test for the occurrence of single allergens in ELISA (Cucu et al. 2012) . 315
This method is however not recommended for endogenous allergenicity assessment, and some 316 problems are comparable to the limitations described above, occurring when human serum IgE is 317 used. Importantly, the animal immune response is highly variable and single allergenic proteins might 318 display only limited immunogenicity compared to others. Therefore, the variety of antibodies present 319 in these sera might be restricted concerning specificity, affinity and concentration. As a consequence, 320 some allergic proteins might be over-or underrepresented, respectively, and some allergens might 321 even be overlooked entirely. Currently, publications regarding quantification are not available for all soybean allergens mentioned 345 in the WHO/IUIS database or for all potential allergens included in the OECD consensus document. As 346 described, there are also discrepancies between publications concerning variability of certain 347 allergenic molecules. However, while this might be a technical issue and therefore depend on the 348 method used, it could also be due to different soybean varieties investigated, and also depend on 349 growth sites of the crops and, therefore, environmental factors. Moreover, possible isoforms in the 350 case of Gly m 4 or subunits of Gly m 5 or Gly m 6 might react with the same antibodies due to 351 structural similarities in ELISA, while these varieties are not detected by MS because of sequence 352 restrictions. To this end, the development of further protocols as well as fine tuning of current 353 approaches should be highly encouraged. In order to be able to compare the allergen content of 354 different soybean varieties, also between research groups, it would be helpful to optimize and 355 standardise ELISA and MS methods. To this end, standardised and harmonised protocols using 356 defined antibodies in ELISA or defined allergen peptides in MS could be developed and applied, 357 providing a basis for optimum quantification and comparison. 358
Data interpretation 359
Determination of endogenous allergen levels should be carried out as a part of the comparative 360 analysis of composition (EC, 2013). Therefore, apart from comparing the GM food to its conventional 361 counterpart, a suitable set of non-GM reference varieties should be assessed in parallel. These 362 varieties can present a set of data on the natural variation of the protein or allergen in question and 363 ideally can provide an upper (and lower) limit of the natural allergen protein content. Any possible 364 changes observed between the GM crop and its conventional counterpart can then, in the next step, 365 be evaluated statistically by taking these varieties and the natural range of endogenous allergenic 366 protein into account. 367
There is a need for better understanding the natural variability of allergens. Industry and research 368 institutes should be strongly encouraged to collect as many data as possible on allergen natural 369 variability of soybean varieties representative of the ones consumed by the at-risk population. In 370 order for these data to be readily usable and comparable, the methodology used should be 371 standardised and harmonised. 372
A solid database containing a broad range of measurements concerning the natural variation of 373 endogenous allergens is the main basis for interpreting data acquired for a new GM variety. The 374 endogenous allergen content of a new GM variety is less likely to raise an uncertainty the more the 375 natural variation of these proteins is understood. In the case a potential allergenic protein differs 376 statistically significant from its non-GM counterpart regarding the concentration of one or several 377 endogenous allergens and additionally falls outside the range of natural variation, the consequences 378 are uncertain and the biological relevance as well as the impact on human health has to be evaluated 379 in the next step. Not only the possible enhanced risk of eliciting an allergic reaction in already allergic 380 individuals has to be assessed, but also the likelihood that new sensitisations might occur to a greater 381 extent due to the enhanced allergen content. To this end, a case-by case approach evaluating 382 additional considerations and/or experimental data might be applied, depending on the specific 383 potential allergen(s) in question, the number of allergens involved, their clinical relevance and the 384 magnitude of the change. While it is currently challenging to evaluate the impact of an enhanced 385 allergen content on sensitisation, the use of dose-distribution curves obtained by DBPCFC are a 386 relevant tool and could be taken into consideration to assess the risk for elicitation of an allergic 387 reaction. However, as mentioned above, dose-distribution curves are not readily available for single 388 allergens, and they are usually obtained by challenging allergic individuals which are not at high risk 389 to encounter an anaphylactic reaction. 390 Dose-distribution curves with a readout for single allergen molecules are in this context especially 391 important for soybean allergy, since, due to several "major" allergens, the allergic individuals are 392 highly heterogeneous. While the ones "truly" sensitised by soybean allergens Gly m 5 or Gly m 6 393 might be at risk if these molecules are enhanced in a GM crop compared to natural varieties, allergic 394 individuals sensitised to the major allergen of birch, Bet v 1, may be highly sensitive to the cross-395 reactive allergen Gly m 4 and, for them, the Gly m 4 content of soybean may be crucially important. 396 Dose-distribution curves obtained by using total soybean protein might therefore be critically skewed 397 depending on the allergic individuals assessed in DBPCFC, and also the quality and allergen content 398 of the challenge material can play a role. Indeed, if the challenge material is well characterised and 399 the allergen-content is known, dose-distribution curves corresponding to a single allergen may be 400 Upon an enhanced endogenous allergen content detected, also exposure considerations might be 418 taken into account as a last step in the risk assessment process. Therefore, the GM food should be 419 further characterized concerning its anticipated intake (EC, 2013) and efforts should concentrate on 420 most at-risk groups. In the case of airborne allergens, the likelihood of exposure to the airways has to 421 be considered. A potentially enhanced allergen content should even strengthen the anticipations of 422 strictly fulfilling safety measures (Pont et al., 1997) . like the strategy applied by WHO/IUIS can be taken as a basis for these considerations. However, due 431 to the constant scientific progress these definitions have to be evaluated on a regular basis and, if 432 necessary, adapted. It is important to pro-actively include clinicians into the risk assessment process, 433 including into defining appropriate molecules to be measured as well as into the final strategies to be 434 applied for the safety assessment to protect consumers, in particular those at higher risk. The natural 435 variability of endogenous allergens in soybeans traditionally consumed by the population is an 436 invaluable tool to interpret data acquired for new varieties generated by biotechnology. 
